Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

To confirm the bearish trend, PFE has been trading below its 50-day moving average since October 2024, experiencing some fluctuations. The stock is trading below its 200-day moving average since ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.